

FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *		2. Issuer Name and Ticker or Trading Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)	
Myers Jason W.		Invitae Corp [NVTA]		<input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)		<input type="checkbox"/> Officer (give title below) <input checked="" type="checkbox"/> Other (specify below)
C/O INVITAE CORPORATION, 1400 16TH STREET			12/14/2020		President, Oncology
(Street)			4. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)
SAN FRANCISCO, CA 94103					<input checked="" type="checkbox"/> Form filed by One Reporting Person
(City)	(State)	(Zip)			<input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/14/2020		A		171872	A	(1)	1211099	D	
Common Stock	12/14/2020		A		152527	A	(1)	1363626	D	
Common Stock	12/16/2020		S(2)		71869	D	\$47.3205	1291757	D	
Common Stock	12/17/2020		S		12082	D	\$46.6375 (4)(5)	1279675	D	
Common Stock	12/17/2020		S		33340	D	\$47.2728 (5)(6)	1246335	D	
Common Stock	12/17/2020		S		5270	D	\$48.2328 (5)(7)	1241065	D	
Common Stock	12/17/2020		G		300000	D	\$0.00	941065	D	
Common Stock	12/18/2020		S		81677	D	\$47.3863 (5)(8)	859388	D	
Common Stock	12/18/2020		S		49474	D	\$48.1808 (5)(9)	809914	D	
Common Stock	12/18/2020		S		200	D	\$48.775 (5)(10)	809714	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

- Received in connection with the achievement of a milestone pursuant to the Agreement and Plan of Merger and Plan of Reorganization, dated as of June 21, 2020, by and among the Issuer, Apollo Merger Sub A Inc., a wholly-owned, direct subsidiary of the Issuer, Apollo Merger Sub B LLC, a wholly-owned, direct subsidiary of the Issuer, ArcherDX, Inc., and Kyle Lefkoff, solely in his capacity as holders' representative.
- Represents the sale of shares to cover tax withholding obligations associated with the issuance of stock.
- The sales of common stock were effected pursuant to a Rule 10b-5 sales plan adopted by the reporting person on October 1, 2020.
- Represents a weighted average sale price. Actual sale prices ranged from \$45.91 to \$46.90 per share.
- Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- Represents a weighted average sale price. Actual sale prices ranged from \$46.91 to \$47.90 per share.
- Represents a weighted average sale price. Actual sale prices ranged from \$47.94 to \$48.90 per share.
- Represents a weighted average sale price. Actual sale prices ranged from \$46.74 to \$47.73 per share.
- Represents a weighted average sale price. Actual sale prices ranged from \$47.74 to \$48.73 per share.
- Represents a weighted average sale price. Actual sale prices ranged from \$48.74 to \$48.81 per share.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Myers Jason W. C/O INVITAE CORPORATION 1400 16TH STREET SAN FRANCISCO, CA 94103	X			President, Oncology

Signatures/s/ Thomas Brida, Attorney-in-Fact12/18/2020

--Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.